A Functional Variant of Elafin With Improved Anti-inflammatory Activity for Pulmonary Inflammation-Reference-Cited by-同舟云学术

A Functional Variant of Elafin With Improved Anti-inflammatory Activity for Pulmonary Inflammation

Published:2015-01 Issue:1 Volume:23 Page:24-31
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Small Donna M,Zani Marie-Louise,Quinn Derek J,Dallet-Choisy Sandrine,Glasgow Arlene MA,O'Kane Cecilia,McAuley Danny F,McNally Paul,Weldon Sinéad,Moreau Thierry,Taggart Clifford C

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference46 articles.

1. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin;Guyot;Biol Chem,2005

2. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core;Schalkwijk;Biochem J,1999

3. Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion;Kramps;Exp Lung Res,1985

4. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis;Schalkwijk;Br J Dermatol,1990

5. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence;Wiedow;J Biol Chem,1990

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymicrobial Biofilms in Cystic Fibrosis Lung Infections: Effects on Antimicrobial Susceptibility;Springer Series on Biofilms;2022-12-19

2. Elafin and its precursor trappin‐2: What is their therapeutic potential for intestinal diseases?;British Journal of Pharmacology;2022-11-28

3. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis;International Journal of Molecular Sciences;2022-01-05

4. Elafin Reverses Intestinal Fibrosis by Inhibiting Cathepsin S-Mediated Protease-Activated Receptor 2;Cellular and Molecular Gastroenterology and Hepatology;2022

5. Therapeutic agents for ARDS;Signa Vitae;2022